Estados financieros detallados de Sagimet Biosciences Inc. (SGMT): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $10.46, SGMT presenta beneficios negativos (P/E no significativo) y un ROE del -31.96%. La capitalización bursátil es de $341M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | $2.0M | 0 | 0 |
| Coste de Ventas | $88000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$88000 | 0 | 0 | 0 | $2.0M | 0 | 0 |
| I+D | $8.4M | $8.2M | $19.3M | $24.9M | $19.8M | $38.4M | $39.1M |
| Generales y Administrativos | $5.7M | $3.2M | $4.4M | $6.1M | $13.0M | $16.0M | $17.8M |
| Gastos Operativos | $14.1M | $11.4M | $23.7M | $31.1M | $32.7M | $54.5M | $56.9M |
| Beneficio Operativo | -$14.2M | -$11.4M | -$23.7M | -$31.1M | -$30.7M | -$54.5M | -$56.9M |
| EBITDA | -$14.1M | -$11.4M | -$24.4M | -$30.4M | -$27.9M | -$45.6M | -$51.0M |
| Gastos por Intereses | $64000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$14.3M | -$11.4M | -$24.4M | -$30.5M | -$27.9M | -$45.6M | -$51.0M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$14.3M | -$11.4M | -$24.4M | -$30.5M | -$27.9M | -$45.6M | -$51.0M |
| BPA | $-0.64 | $-0.51 | $-1.10 | $-1.38 | $-1.53 | $-1.45 | $-1.58 |
| BPA Diluido | $-0.64 | $-0.51 | $-1.10 | $-1.38 | $-1.53 | $-1.45 | $-1.58 |
| Acciones en Circulación (Diluidas) | $22.2M | $22.2M | $22.2M | $22.2M | $18.2M | $31.4M | $32.3M |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $10.2M | $68.7M | $56.7M | $158000 | $75.1M | $75.8M | $35.0M |
| Inversiones a Corto | 0 | 0 | 0 | $32.2M | $19.8M | $75.4M | $78.1M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $10.8M | $68.7M | $58.7M | $32.8M | $96.6M | $152.8M | $116.4M |
| Inmovilizado Material | $318000 | $194000 | $342000 | $212000 | $73000 | $77000 | $78000 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $11.2M | $69.0M | $59.0M | $33.0M | $96.7M | $160.3M | $116.5M |
| Cuentas por Pagar | $1.2M | $513000 | $761000 | $1.1M | $186000 | $1.4M | $1.3M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $2.1M | $1.9M | $2.4M | $5.3M | $5.7M | $4.5M | $5.1M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $136.5M | $204.9M | $217.3M | $220.0M | $5.7M | $4.5M | $5.1M |
| Reservas | -$155.6M | -$166.9M | -$191.4M | -$221.9M | -$249.7M | -$295.3M | -$346.3M |
| Patrimonio Neto | -$125.3M | -$135.9M | -$158.3M | -$186.9M | $91.1M | $155.8M | $111.4M |
| Deuda Total | $341000 | $210000 | $348000 | $211000 | $65000 | $78000 | $78000 |
| Deuda Neta | -$9.9M | -$68.5M | -$56.4M | -$32.1M | -$94.8M | -$151.2M | -$113.0M |
| Capital Circulante | $8.7M | $66.8M | $56.2M | $27.5M | $91.0M | $148.3M | $111.3M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$14.3M | -$11.4M | -$24.4M | -$30.5M | -$27.9M | -$45.6M | -$51.0M |
| Amortizaciones | $1000 | 0 | 0 | $130000 | 0 | 0 | 0 |
| Compensación en Acciones | $3.0M | $775000 | $1.9M | $1.9M | $5.0M | $5.3M | $6.4M |
| Cambio en Capital Circulante | $645000 | $75000 | -$55000 | $4.2M | -$978000 | -$1.0M | -$1.1M |
| Flujo de Caja Operativo | -$10.6M | -$10.4M | -$21.7M | -$24.5M | -$23.8M | -$42.4M | -$45.6M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$10.6M | -$10.4M | -$21.7M | -$24.5M | -$23.8M | -$42.4M | -$45.6M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -100.0% | ||||||
| Crecimiento Beneficio Neto (anual) | +20.3% | -115.0% | -24.8% | +8.6% | -63.5% | -12.0% | |
| Crecimiento BPA (anual) | +20.3% | -115.7% | -25.5% | -10.9% | +5.2% | -9.0% | |
| Cambio en Acciones (anual) | +0.0% | +0.0% | +0.0% | -17.9% | +72.3% | +3.2% | |
| Crecimiento FCF (anual) | +1.3% | -108.4% | -12.8% | +3.0% | -78.6% | -7.6% | |
| Margen Bruto | 100.0% | ||||||
| Margen Operativo | -1537.0% | ||||||
| Margen EBITDA | -1393.8% | ||||||
| Margen Neto | -1393.8% | ||||||
| Margen FCF | -1188.3% | ||||||
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.48 | $-0.47 | $-0.98 | $-1.10 | $-1.31 | $-1.35 | $-1.41 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $22.2M | $22.2M | $22.2M | $22.2M | $18.2M | $31.4M | $32.3M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -31.96% |
| Rentabilidad sobre capital invertido | -20.39% |
| Rentabilidad sobre activos | -17.87% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 45.02 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -24.92 | -31.27 | -14.50 | -11.56 | -3.54 | -3.10 | -3.75 |
| P/VC | -2.82 | -2.60 | -2.23 | -1.89 | 1.08 | 0.91 | 1.72 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 49.31 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | -1537.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | -1393.8% | 0.0% | 0.0% |
Empresas relacionadas: ACHV · ARCT · ASMB · AVIR · FHTX · HUMA · IMRX
Explorar sector: Healthcare · Biotechnology
Más secciones de SGMT: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones